Journal
TUMOR BIOLOGY
Volume 37, Issue 6, Pages 7245-7254Publisher
SPRINGER
DOI: 10.1007/s13277-015-4604-7
Keywords
Gemcitabine resistance; miR-21; Epithelial to mesenchymal transition (EMT); Breast cancer
Categories
Funding
- National Natural Science Foundation of China [81372846, 81402188]
Ask authors/readers for more resources
Acquisition of gemcitabine resistance in breast cancer has not been fully clarified. Prior studies suggest that miRNAs are important to chemoresistance in solid tumors and we confirmed that miR-21 is involved in the development of gemcitabine resistance. Epithelial-to-mesenchymal transition (EMT) and AKT pathway activation were noted to be important to this resistance as well. PTEN, a direct target gene of miR-21, was significantly downregulated in gemcitabine-resistant breast cancer cells and restoration of PTEN expression blocked miR-21-induced EMT and gemcitabine resistance. Our data offer novel insight into gemcitabine resistance in breast cancer and suggest that miR-21 may be used to predict optimal breast cancer therapy and may be a potential therapeutic target for reversing gemcitabine resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available